About
Technology
Issues
FAQ
Search
Profile
Top Authors
Prolific Authors
Top Journals
Main Disciplines
Main Topics
Most Cited Articles
Scientometrics
Avg Impact Factor
★★
Articles
★★★
Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Schools
›
Division of Medical Oncology
›
top-articles
Division of Medical Oncology
133
(top 1%)
papers
1.5K
(top 2%)
citations
12
(top 2%)
h
-index
39
(top 1%)
g
-index
136
all documents
1.7K
doc citations
572
citing journals
Top Articles
#
Title
Journal
Year
Citations
1
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials
Annals of Oncology
2017
654
2
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
The Lancet Gastroenterology and Hepatology
2021
205
3
FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer
European Journal of Cancer
2015
202
4
Cancer Dormancy: A Model of Early Dissemination and Late Cancer Recurrence
Clinical Cancer Research
2012
173
5
<p>Current status of liquid biopsies for the detection and management of prostate cancer</p>
Cancer Management and Research
2019
47
6
The importance of surgical margins in breast cancer
Journal of Surgical Oncology
2016
37
7
Surgery and adjunctive chemotherapy for invasive bladder cancer
Surgical Oncology
2002
31
8
Chemotherapy and cystectomy for invasive transitional cell carcinoma of bladder
Urologic Oncology: Seminars and Original Investigations
2003
28
9
Development and Application of Liquid Biopsies in Metastatic Prostate Cancer
Current Oncology Reports
2018
28
10
Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer
Investigational New Drugs
2019
22
11
AXIN2
expression predicts prostate cancer recurrence and regulates invasion and tumor growth
Prostate
2016
14
12
Frequency of BRCA mutation in biliary tract cancer and its correlation with tumor mutational burden (TMB) and microsatellite instability (MSI).
Journal of Clinical Oncology
2019
12
13
Association of
BRCA
-mutant pancreatic cancer with high tumor mutational burden (TMB) and higher PD-L1 expression.
Journal of Clinical Oncology
2019
12
14
Pharmacogenomics and metastatic colorectal cancer: Current knowledge and perspectives
Scandinavian Journal of Gastroenterology
2012
11
15
Baseline Glomerular Filtration Rate and Cisplatin- Induced Renal Toxicity in Urothelial Cancer Patients
Clinical Genitourinary Cancer
2018
11
16
Malignancy rates after surgical excision of discordant breast biopsies
Journal of Surgical Research
2015
10
17
Leptomeningeal carcinomatosis in sinonasal undifferentiated carcinoma
Head and Neck
2013
9
18
Impact of timing of administration of bone supportive therapy on pain palliation from radium-223
Cancer Treatment and Research Communications
2019
9
19
Clinical value of atezolizumab + bevacizumab for first-line unresectable hepatocellular carcinoma (HCC): A network meta-analysis.
Journal of Clinical Oncology
2020
8
20
Characteristics of patients (pts) with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) who had progression-free survival (PFS) >4 months (m): Subgroup analysis of the phase 3 CORRECT trial
Annals of Oncology
2016
7
21
GDF15 expression in metastatic colorectal cancer.
Journal of Clinical Oncology
2021
7
22
Molecular landscape of colorectal cancers harboring R-spondin fusions.
Journal of Clinical Oncology
2019
7
23
A phase II, open-label study of tomivosertib (eFT508) added on to continued checkpoint inhibitor therapy in patients (pts) with insufficient response to single-agent treatment.
Journal of Clinical Oncology
2020
7
24
Comprehensive molecular profiling of
IDH1/2
mutant biliary cancers (BC).
Journal of Clinical Oncology
2020
7
25
‘Active surveillance’ for stage I testis cancer
European Journal of Cancer
2000
6
26
High CXCR4 expression in pancreatic ductal adenocarcinoma as characterized by an inflammatory tumor phenotype with potential implications for an immunotherapeutic approach.
Journal of Clinical Oncology
2021
6
27
The landscape of DNA damage response (DDR) pathway in colorectal cancer (CRC).
Journal of Clinical Oncology
2020
6
28
Characteristics of colorectal cancer (CRC) patients with BRCA1 and BRCA2 mutations.
Journal of Clinical Oncology
2019
5
29
Chemotherapy for Good-Risk Nonseminomatous Germ Cell Tumors
Urologic Clinics of North America
2015
4
30
Chemotherapy for oligometastatic prostate cancer
Current Opinion in Urology
2017
4
31
Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses
Clinical Colorectal Cancer
2019
4
32
MORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT) combinations in patients (pts) with gastric or pancreatic cancer.
Journal of Clinical Oncology
2018
4
33
Genetic variations within the CD40L immune stimulating gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab: Data from FIRE-3 and TRIBE.
Journal of Clinical Oncology
2019
4
34
Circulating tumor cells in prostate cancer: a better predictor of survival than prostate specific antigen?
Expert Review of Anticancer Therapy
2014
3
35
Single nucleotide polymorphisms (SNPs) in endoplasmic reticulum (ER) stress response genes to predict first-line treatment outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from the MAVERICC and FIRE-3 trials.
Journal of Clinical Oncology
2021
3
36
Genetic variants of ATM and XRCC3 to predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.
Journal of Clinical Oncology
2016
3
37
Polymorphisms in toll-like receptor (TLR) genes in the prediction of outcome for cetuximab-based treatment in patients with metastatic colorectal cancer (mCRC).
Journal of Clinical Oncology
2016
3
38
BRCA1 genetic variant to predict survival in metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI/bevacizumab (bev): Results from phase III TRIBE and FIRE-3 trials.
Journal of Clinical Oncology
2019
3
39
Gene mutations of SWI/SNF complex and molecular profile in colorectal cancer.
Journal of Clinical Oncology
2019
3
40
A phase I/II multisite study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) in patients with locally advanced esophageal squamous cell carcinoma (ESCC).
Journal of Clinical Oncology
2020
3
41
Selecting the best targeted agent in first‐line treatment of unresectable liver metastases from colorectal cancer: does the bench have the answers?
Journal of Hepato-Biliary-Pancreatic Sciences
2012
2
42
Identification and prognostic impact of
PBRM1
mutations in biliary tract cancers: Results of a comprehensive molecular profiling study.
Journal of Clinical Oncology
2021
2
43
Genetic variants of
hENT-1
to predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.
Journal of Clinical Oncology
2016
2
44
Role of genetic polymorphisms in CCL5/CCR5 axis to predict efficacy of regorafenib in patients with refractory metastatic colorectal cancer.
Journal of Clinical Oncology
2017
2
45
Circadian clock gene PER1 mutations in colorectal cancer (CRC).
Journal of Clinical Oncology
2018
2
46
Polymorphism in the circadian clock pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials.
Journal of Clinical Oncology
2018
2
47
Phase II multicenter pilot study of safety, efficacy, and immune cell profiling in advanced hepatocellular carcinoma (HCC) on combination of sorafenib (SOR) plus nivolumab (NIVO).
Journal of Clinical Oncology
2019
2
48
AGEN1181, a clinical stage Fc-engineered anti-CTLA-4 antibody with improved therapeutic potential for the treatment of patients with advanced malignancies.
Journal of Clinical Oncology
2020
2
49
Genetic variants in immune response genes to predict clinical outcome in mCRC patients treated with FOLFIRI/cetuximab (FIRE-3) or with first line cetuximab-based chemotherapy (JACCRO CC-05/06 AR).
Journal of Clinical Oncology
2016
2
50
Urethral Cancer
2006
1
site/software ©
exaly
; All materials licenced under
CC by-SA
.